Correlation between coronary heart disease and lipoprotein size and composition is well documented. Within the low-density lipoprotein (LDL) family the small LDL particles are associated with increased risk of coronary heart disease. These particles also have increased apolipoprotein (apo) B content. The appearance of these small LDL particles is the manifestation of complex alteration of plasma lipoprotein metabolism. The LDL size is influenced by genetic, endocrine, and environmental factors. Within the high-density lipoprotein (HOL) family the decrease of larger HDL2 particles is associated with coronary heart disease. HDLs can also be separated according to their apoprotein composition into particles containing lipoprotein (Lp)A-l only and particles containing LpA-l and LpA-ll. Most studies have shown that the concentration of LpA-l-only particles decreases in coronary heart disease. HDL5 are remodeled in the circulation and this remodeling continues in vitro after the blood is taken. Therefore adequate preservation of blood samples is necessary. ape, apolipoprotein; CETP, cholesteryl ester transfer protein; HDL, LDL, VLDL, high-, low-, and very-low-density lipoprotein, respectively; HMG CoA, 3-hydroxy-3-methylglutaryl coenzyme A; LpA-I, -II, lipoproteins A-I and A-Il; and LCAT, lecithin:cholesteryl acyltransferase.
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Low-Density Lipoproteins
LDLs have a hydrated density of 1.019 to 1.063 kg/L and a diameter of 20 to 30 nm. On paper or agarose electrophoresis, they display p mobffity (6) . where it could be subjected to oxidation longer; it is also more easily oxidized in vitro (21) (22) (23) (32) . In the same mechanism, the triglyceride will replace the transferred cholesteryl esters, and the LDL will be enriched in triglyceride.
The
This triglyceride-rich LDL is subjected to the action of lipoprotein lipase, resulting in a lipid-poor, protein-rich, smaller, denser LDL particle (33).
High-Density Lipoproteins
HDLs are the anti-atherogenic lipoproteins; they influence the retardation or regression of the atherosclerotic process (34). The structure of HDL is more complex than LDL. On the surface of the particle are the apoproteins, phospholipid, and free cholesterol. Cholesteryl esters and small amounts of triglyceride are present in the core. HDLs contain several apoproteins;
their major apoprotein is apoA-I and apoA-II, but apoE, apoA-W, and the C apoproteins are also present. (42) . These data showed that both HDL2 and HDL3 concentrations were reduced in coronary heart disease, the reduction of HDL2 being proportionally greater than for HDL3. Similar observations were reported by Gofman et al. in a prospective study in 1966 (43); they found that subjects who developed coronary heart disease had a decrease of HDL2 and HDL3, but the association of coronary heart disease was greater with the decrease of HDL2. A recent prospective study (44) and other studies confirmed the decrease of HDL2 and HDL3, but the decrease in HDL3 was a stronger predictor of coronary heart disease than HDL2.
A major contributor for the variance in the reported findings are the differences in the techniques of the isolation of HDL subfractions (ultracentrifugation or polyanion precipitation).
Most studies did not consider the role of sample preservation, which influences the results. Careful attention should be placed on the collection and storage of blood. Samples should include, in addition to bactericidal compounds, inhibitors of protease and LCAT.
Currently, it is difficult to conclude unequivocally whether the decrease of HDL2 or HDL3 is a better predictor of coronary heart disease. Total HDL cholesterol is as good, if not better, a predictor of coronary heart disease as HDL2 or HDL3 (44) -I-only particles (46) . They also identified lipoprotein particles containing both apoA-I and apoA-ll, referring to them as LpA-I with LpA-II particles. The LpA-I-only particle is larger (9.98-nm diameter vs 7.65 nm for the LpA-I with LpA-II) (47) . LpA-Ionly is believed to be mainly associated with HDL2, whereas the LpA-I with LpA-II particles predominate in HDL3 (48). This arrangement may contribute to the findings that a decrease of HDL2 correlates better with coronary heart disease than does HDL3. In control plasma, 30% to 40% of total apoA-I is present in LpA-Ionly particles, and the LpA-I with LpA-II represents 60% to 70% of the total apoA-I (49 
days) (55).
In a study comparing controls with normolipidemic patients with angiographically proven coronary heart disease, the concentrations of LpA-I-only particles were lower and the concentrations of LpA-I with LpA-II were similar to those in the controls (56). Similar studies were performed on patients with higher triglyceride concentrations than those of controls (57) : Contrary to the previous findings, both LpA-I-only and LpA-I with LpA-II particles were found to be decreased in a similar degree in coronary heart disease patients.
Women also have slightly higher LpA-I-only and lower concentrations of LpA-I with LpA-II particles than men (49). A comparison of populations from separate geographic areas with different mortality rates of myocardial infarctions showed that populations with the highest mortality rate for myocardial infarction had the lowest LpA-I-only concentrations (58) . Diets and drugs also influence the concentrations of these particles (Table 1) The protein standards run simultaneously in the same gel provide a reference for size determination.
The schematic representation of the individual subpopulation in Fig. 2 identifies several pre-/3, a, and pro-a particles.
For each subpopulation, an Rf value relative to albumin, size, and quantitation of apoA-I can be obtained. the same particles; however, absence of co-localization with apoA-II is an indication that it is a particle that contains apoA-I only. Interestingly, this is the case for pro-fl1: The apoA-II did not co-localize with apoA-I, suggesting that pro-fl1 is an LpA-I-only particle (unpublished observation).
In conclusion, the correlation between coronary heart disease and small, dense LDL (phenotype B) or hyperapobetalipoproteinemia is well documented and generally accepted; it is influenced by genetic, environmental, and endocrine factors.
The small size of LDL is not an independent atherogenic risk factor; instead, it is closely tied to triglyceride metabolism and is a manifestation of a complex alteration of plasma lipoprotein metabolism. The findings on the correlation of Hl)L subpopulations and coronary heart disease are clearly less consistent. Tentatively and with reservation, we think the available data suggest that LpA-I-only particles may represent the anti-atherogenic particle within HDL. One explanation for the differences in the results obtained for HDL subpopulations is related to the physiology of HDL: HDLs undergo continuous remodeling in vivo, which continues in vitro after blood samples are drawn and will influence the distribution of subpopulations. Thus, appropriate preservation of samples is necessary to obtain quality information. Currently, two-dimensional electrophoresis is only a research tool and cannot be used for large-scale epidemiologic studies. However, well-controlled studies using this system should contribute to a better understanding of HDL subpopulations and their possible connection to coronary heart disease.
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